Home » Healthcare » Bacterial Pneumonia Market

Bacterial Pneumonia Market By Disease Type (Community-acquired Pneumonia, Healthcare-associated Pneumonia) By Drug Type (Antibiotics, Cough Medicine, Pain Killer/Fever Reducers, Vaccines) By Dosage Form (Oral, Intravenous) – Growth, Future Prospects & Competitive Analysis, 2016 – 2028

Price: $4999

Published: | Report ID: 2086 | Report Format : PDF

About this report

The global Bacterial Pneumonia Market report explores the critical analysis of the Bacterial Pneumonia industry using key parameters. The report consists of investment strategies, the need for investments in the Bacterial Pneumonia industry, and the multiple benefits for the investors. Importantly, this report sets out major changes in the global technical regulations for the Bacterial Pneumonia industry, as well as how economic and non-economic barriers are helping the Bacterial Pneumonia market grow. Moreover, the report analyzes the global, regional, and country-level historic and forecasted market size. The report also provides a comprehensive analysis of key investment propositions, demand and supply gap, competitors positioning, STAR analysis, SRC analysis, Tornado analysis. key technological developments, and other analyses such as porter’s five forces analysis, PESTEL analysis, value chain analysis, etc.

Bacterial Pneumonia Market

Key Highlights of the report

How are the major segments performing in the Bacterial Pneumonia Market?

In 2021, community-acquired pneumonia was the leading segment in the disease type. The expansion of the number of active clinical studies for the creation of therapeutic molecules greatly impacts how quickly the market develops. Merck and GSK are two businesses now investing much time and energy in research and development for pneumonia treatments.

In 2021, antibodies led the bacterial pneumonia industry, and this trend is anticipated to remain for the entire projection period. The introduction of generic medications to the market is responsible for this constant growth. Growing regulatory pressure on physicians in emerging nations to prescribe generics, recent patent expirations of branded pharmaceuticals, the affordability of generics, and recent patent expirations of branded drugs all increase growth possibilities.

In 2021, drugs in dosage form will lead the market. Drug solubility and the degree of protein binding impact the strength of their effectiveness because of their varying penetration to various target locations of infection.

Online pharmacies were the market segment with the highest CAGR during the projection period. Online pharmacies provide more affordable prices with lower transaction and product expenses than physical pharmacies. Online pharmacies also provide accessibility and convenience to those with limited mobility. These pharmacies also offer doorstep delivery promptly, which boosts customer preference.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Which region dominated the Bacterial Pneumonia Market?

In 2021, North America was one of the major contributors to the global Bacterial Pneumonia market. Due to the increased prevalence of community-acquired pneumonia in the region, particularly in the U.S.is predicted to have a leading position in the global market for medications used to treat CABP. For instance, an article from the Asian Pacific Society of Respirology in 2017 states that while the overall incidence of community-acquired pneumonia in adults in the United States was around 2.5 per 1000 people, it increased to 6.3 and 16.4 per 1000 people in adults 65 and older and adults aged 79 and older, respectively.

What is the competitive environment of the Bacterial Pneumonia Market?

The competitive landscape of the Bacterial Pneumonia industry provides data on the overall economic profit made by vendors and businesses, the sales and revenues generated in this industry, the Bacterial Pneumonia market share globally, an overview of business organizations, the introduction of new products, and opportunities for the industrial Bacterial Pneumonia market. For instance, Zerbaxa was given FDA approval by Merck in June 2019. This medication is used to treat hospital-acquired bacterial pneumonia and pneumonia linked with ventilators. The firm’s portfolio of pneumonia treatments was expanded by this method. On the other hand, Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine was given the breakthrough therapy designation by the U.S. FDA in September 2018. This vaccination is helpful in preventing invasive illness and pneumonia. This tactic improved the company’s line of products.

Executive Summary

What is the opportunity in the Bacterial Pneumonia Industry Market?

Regarding market opportunity for pneumonia testing, there has been a change in consumer desire and a rise in the need for point-of-care diagnostic solutions over time. There is a critical need for quick diagnostic tools due to the increased prevalence of pneumonia. The point-of-care testing market has gained popularity among medical professionals and patients due to its major advantages, including convenience, quicker diagnosis, and better treatment outcomes. Rapid syndromic molecular assays for pneumonia give more diagnosis accuracy than the current gold standard of culture, according to an NCBI publication from January 2020. The research study contrasted a traditional diagnostic approach with the commercially available syndromic diagnostic testing Distribution channels, such as the Filmarray Pneumonia panel and Unyvero, and discovered that the first two items were more effective in detecting pneumonia. To combat the growing burden of the disease, major industry players are also aggressively creating point-of-care molecular diagnostics for early identification of pneumonia. For instance, the U.S. FDA approved the ImmuView S pneumoniae and L pneumophila Urinary Antigen Test in March 2020 for SSI Diagnostica A/S. It is a quick, lateral flow test recommended for finding antigens of Legionella pneumophila and Streptococcus pneumoniae in urine samples.

Which are the major investments by the players in the Bacterial Pneumonia Industry Market?

Systems to prevent bacterial pneumonia have been employed in various industries because of their excellent adaptability and versatility. The main participant makes numerous investments; for instance, The Medicines Company received an initial grant from the Biomedical Advanced Research and Development Authority of USD 32 million in 2018, and it will receive an additional USD 100 million over five years to develop a portfolio of next-generation antibiotics that are expected to help in the fight against drug-resistant infections.

Some of the major companies in the market are Pfizer, Inc., Eli Lilly and Company, Lupin Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries, Ltd, Mylan N.V., Sanofi, AstraZeneca plc, GlaxoSmithKline plc, and Nabriva Therapeutics plc..

What are the Major Dynamics Factors for the Bacterial Pneumonia Market?

Due to the rise in bacterial resistance, antibiotics are losing their ability to treat bacterial pneumonia. New antibiotic prospects are the subject of ongoing innovation in the pharmaceutical sector. This is anticipated to accelerate the rate at which bacterial pneumonia is cured shortly. In addition, rising rates of community-acquired pneumonia, particularly in younger people, are a major driver of market expansion. According to the WHO, children in underdeveloped nations account for 95% of all pneumococcal episodes.

What are the Major Risks for the Bacterial Pneumonia Market?

Over time, regulatory authorities’ processes for approving medications for bacterial pneumonia have become more complicated, impractical, and possibly irrelevant to patients and clinicians. Additionally, the cost and duration of drug development are greatly increased by scientific and regulatory hurdles, which exacerbates the financial disadvantages of bacterial pneumonia medications. Regulatory authorities do not support the revision and streamlining of the anti-bacterial drug research and licensing process due to the urgency of bacterial drug resistance and the potential for targeted diseases to evolve significantly over time.

Which is the key Drug Type in the Bacterial Pneumonia Market?

The antibodies sector dominated the bacterial pneumonia market in 2021. A special kind of antibody is used to treat bacterial pneumonia. A class of antibiotics known as aminopenicillin is typically used to treat upper and lower respiratory tract infections. According to the Infectious Disease Society of America, the first-line treatment for community-acquired pneumonia is the penicillin-like medication amoxicillin. When amoxicillin binds to penicillin-binding proteins, an autolytic enzyme is activated, which breaks down the bacterial cell wall and kills the bacterial cell. According to a 2017 study published in the Journal of Infection, the number of hospital stays is larger in the case of adults, putting them at a higher risk of developing hospital-acquired pneumonia. Additionally, according to a 2017 study in Age and Ageing, 1.5% of persons have pneumonia that they contracted while in the hospital. Thus, the market in this sector is anticipated to be driven by the rising prevalence of pneumonia in the geriatric population and the development of products.

How is the Bacterial Pneumonia Market performing in regions?

In 2021, the global bacterial pneumonia market was dominated by North America. Because of the rising number of product approvals and the burden of pneumonia infection. Over 250,000 people in the United States receive treatment for pneumonia each year, and 50,000 people pass away as a result, according to the Centers for Disease Control and Prevention. Additionally, the US FDA approved Xenleta by Nabriva Therapeutics plc in 2019 to treat people with community-acquired pneumonia infection. Thus, it is anticipated that these variables will benefit the market for pneumonia treatments. Over 900,000 Americans contract the streptococcus pneumoniae virus each year, according to the American Lung Association. This highlights the necessity for the creation of advanced generation treatments and can be ascribed to the growing elderly population and the rise in adult and paediatric multidrug resistance. As a result, players in the global market are increasing their R&D spending and concentrating on new product development efforts.

Additionally, numerous government programs for diagnosing, treating, and preventing pneumonia have had a favorable effect across North America. For instance, UNICEF and WHO’s Integrated Global Action Plan for Pneumonia and Diarrhea aims to reduce child fatalities from diarrhea and pneumonia that could have been prevented. This project is concentrated on treatments and services that promote access to treatment and preventive measures while increasing awareness.

What is the regulatory landscape for the Bacterial Pneumonia Market?

Governments are examining the regulatory environment for this market as they consider a more stringent regulatory approach regionally. The FDA, PMDA, and EMA concluded in 2016 that a more structured and in-depth conversation and in-person meetings were necessary to clarify the differences and consider solutions.

What is the Market Size of Bacterial Pneumonia regarding value?

In the future, the global market for bacterial pneumonia will be expected to expand at a sizable CAGR of XX%. By 2028, the market for bacterial pneumonia was predicted to be worth USD XX billion, up from USD XX billion in 2021.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

What are key players planning for the future of the Bacterial Pneumonia Market?

Due to several national and international competitors, the competitive landscape of the worldwide market is fragmented. To increase market revenue, however, prominent industry competitors have relied on techniques including product launches and a concentration on mergers and acquisitions.

Segmentation of Global Bacterial Pneumonia Market-

Global Bacterial Pneumonia Market – By Disease Type

  • Community-acquired Pneumonia
  • Healthcare-associated Pneumonia

Global Bacterial Pneumonia Market – By Drug Type

  • Antibiotics
  • Cough Medicine
  • Pain Killer/Fever Reducers
  • Vaccines

Global Bacterial Pneumonia Market – By Dosage Form

  • Oral
  • Intravenous

Global Bacterial Pneumonia Market – By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Bacterial Pneumonia Market – By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Approach Adopted
1.3.4.1. Top-Down Approach
1.3.4.2. Bottom-Up Approach
1.3.5. Assumptions
1.4. Market Segmentation

2. Executive Summary
2.1. Market Snapshot: Global Bacterial Pneumonia Market
2.2. Global Bacterial Pneumonia Market, By Disease Type
2.3. Global Bacterial Pneumonia Market, By Drug Type
2.4. Global Bacterial Pneumonia Market, By Dosage Form
2.5. Global Bacterial Pneumonia Market, By Distribution Channel
2.6. Global Bacterial Pneumonia Market, By Region

3. Market Dynamics & Factors Analysis
3.1. Introduction
3.1.1. Global Bacterial Pneumonia Market Value, 2016-2028, (US$ Bn)
3.2. Market Dynamics
3.2.1. Key Growth Trends
3.2.2. Market Drivers
3.2.3. Market Restraints
3.2.4. Market Opportunities
3.2.5. Major Industry Challenges
3.3. Attractive Investment Proposition,2021
3.3.1. Disease Type
3.3.2. Drug Type
3.3.3. Dosage Form
3.3.4. Distribution Channel
3.3.5. Geography

4. Premium Insights
4.1. STAR (Situation, Task, Action, Results) Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers/Consumers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitute Types
4.2.5. Intensity of Competitive Rivalry
4.3. Value Chain Analysis
4.4. Technology Analysis
4.5. Marketing Strategy Analysis
4.5.1. Direct Marketing
4.5.2. Indirect Marketing
4.5.3. Marketing Channel Development Trend

5. Market Positioning of Key Players, 2021
5.1. Company market share of key players, 2021
5.2. Competitive Benchmarking
5.3. Market Positioning of Key Vendors
5.4. Geographical Presence Analysis
5.5. Major Strategies Adopted by Key Players
5.5.1. Key Strategies Analysis
5.5.2. Mergers and Acquisitions
5.5.3. Partnerships
5.5.4. Product Launch
5.5.5. Geographical Expansion
5.5.6. Others

6. COVID 19 Impact Analysis
6.1. Global Bacterial Pneumonia Market Pre Vs Post COVID 19, 2019 – 2028
6.2. Impact on Import & Export
6.3. Impact on Demand & Supply

7. Global Bacterial Pneumonia Market
7.1. Global Bacterial Pneumonia Market, by Disease Type, 2016-2028(US$ Bn)
7.1.1. Overview
7.1.2. Global Bacterial Pneumonia Market, By Disease Type, 2021 vs 2028 (in%)
7.1.3. Global Bacterial Pneumonia Market, By Community-acquired Pneumonia, 2016-2028 (US$ Bn)
7.1.4. Global Bacterial Pneumonia Market, By Healthcare-associated Pneumonia, 2016-2028 (US$ Bn)
7.2. Global Bacterial Pneumonia Market, by Drug Type, 2016-2028(US$ Bn)
7.2.1. Overview
7.2.2. Global Bacterial Pneumonia Market, By Drug Type, 2021 vs 2028 (in%)
7.2.3. Global Bacterial Pneumonia Market, By Antibiotics, 2016-2028 (US$ Bn)
7.2.4. Global Bacterial Pneumonia Market, By Cough Medicine, 2016-2028 (US$ Bn)
7.2.5. Global Bacterial Pneumonia Market, By Pain Killer/Fever Reducers, 2016-2028 (US$ Bn)
7.2.6. Global Bacterial Pneumonia Market, By Vaccines, 2016-2028 (US$ Bn)
7.3. Global Bacterial Pneumonia Market, by Dosage Form, 2016-2028(US$ Bn)
7.3.1. Overview
7.3.2. Global Bacterial Pneumonia Market, By Dosage Form, 2021 vs 2028 (in%)
7.3.3. Global Bacterial Pneumonia Market, By Oral, 2016-2028 (US$ Bn)
7.3.4. Global Bacterial Pneumonia Market, By Intravenous, 2016-2028 (US$ Bn)
7.4. Global Bacterial Pneumonia Market, by Distribution Channel, 2016-2028(US$ Bn)
7.4.1. Overview
7.4.2. Global Bacterial Pneumonia Market, By Distribution Channel, 2021 vs 2028 (in%)
7.4.3. Global Bacterial Pneumonia Market, By Hospital Pharmacies, 2016-2028 (US$ Bn)
7.4.4. Global Bacterial Pneumonia Market, By Retail Pharmacies, 2016-2028 (US$ Bn)
7.4.5. Global Bacterial Pneumonia Market, By Online Pharmacies, 2016-2028 (US$ Bn)

8. North America Bacterial Pneumonia Market Analysis
8.1. North America Bacterial Pneumonia Market, by Disease Type, 2016-2028(US$ Bn)
8.1.1. Overview
8.1.2. SRC Analysis
8.2. North America Bacterial Pneumonia Market, by Drug Type, 2016-2028(US$ Bn)
8.2.1. Overview
8.2.2. SRC Analysis
8.3. North America Bacterial Pneumonia Market, by Dosage Form, 2016-2028(US$ Bn)
8.3.1. Overview
8.3.2. SRC Analysis
8.4. North America Bacterial Pneumonia Market, by Distribution Channel, 2016-2028(US$ Bn)
8.4.1. Overview
8.4.2. SRC Analysis
8.5. North America Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
8.5.1. U.S.
8.5.1.1. U.S. Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.5.1.2. U.S. Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
8.5.1.3. U.S. Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
8.5.1.4. U.S. Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
8.5.1.5. U.S. Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
8.5.2. Canada
8.5.2.1. Canada Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
8.5.2.2. Canada Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
8.5.2.3. Canada Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
8.5.2.4. Canada Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
8.5.2.5. Canada Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)

9. Europe Bacterial Pneumonia Market Analysis
9.1. Europe Bacterial Pneumonia Market, by Disease Type, 2016-2028(US$ Bn)
9.1.1. Overview
9.1.2. SRC Analysis
9.2. Europe Bacterial Pneumonia Market, by Drug Type, 2016-2028(US$ Bn)
9.2.1. Overview
9.2.2. SRC Analysis
9.3. Europe Bacterial Pneumonia Market, by Dosage Form, 2016-2028(US$ Bn)
9.3.1. Overview
9.3.2. SRC Analysis
9.4. Europe Bacterial Pneumonia Market, by Distribution Channel, 2016-2028(US$ Bn)
9.4.1. Overview
9.4.2. SRC Analysis
9.5. Europe Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
9.5.1. Germany
9.5.1.1. Germany Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.5.1.2. Germany Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
9.5.1.3. Germany Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
9.5.1.4. Germany Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
9.5.1.5. Germany Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
9.5.2. France
9.5.2.1. France Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.5.2.2. France Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
9.5.2.3. France Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
9.5.2.4. France Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
9.5.2.5. France Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
9.5.3. UK
9.5.3.1. UK Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.5.3.2. UK Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
9.5.3.3. UK Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
9.5.3.4. UK Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
9.5.3.5. UK Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
9.5.4. Italy
9.5.4.1. Italy Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.5.4.2. Italy Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
9.5.4.3. Italy Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
9.5.4.4. Italy Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
9.5.4.5. Italy Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
9.5.5. Spain
9.5.5.1. Spain Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.5.5.2. Spain Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
9.5.5.3. Spain Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
9.5.5.4. Spain Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
9.5.5.5. Spain Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
9.5.6. Rest of Europe
9.5.6.1. Rest of Europe Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
9.5.6.2. Rest of Europe Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
9.5.6.3. Rest of Europe Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
9.5.6.4. Rest of Europe Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
9.5.6.5. Rest of Europe Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)

10. Asia Pacific Bacterial Pneumonia Market Analysis
10.1. Asia Pacific Bacterial Pneumonia Market, by Disease Type, 2016-2028(US$ Bn)
10.1.1. Overview
10.1.2. SRC Analysis
10.2. Asia Pacific Bacterial Pneumonia Market, by Drug Type, 2016-2028(US$ Bn)
10.2.1. Overview
10.2.2. SRC Analysis
10.3. Asia Pacific Bacterial Pneumonia Market, by Dosage Form, 2016-2028(US$ Bn)
10.3.1. Overview
10.3.2. SRC Analysis
10.4. Asia Pacific Bacterial Pneumonia Market, by Distribution Channel, 2016-2028(US$ Bn)
10.4.1. Overview
10.4.2. SRC Analysis
10.5. Asia Pacific Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
10.5.1. China
10.5.1.1. China Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.5.1.2. China Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
10.5.1.3. China Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
10.5.1.4. China Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
10.5.1.5. China Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
10.5.2. Japan
10.5.2.1. Japan Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.5.2.2. Japan Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
10.5.2.3. Japan Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
10.5.2.4. Japan Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
10.5.2.5. Japan Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
10.5.3. India
10.5.3.1. India Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.5.3.2. India Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
10.5.3.3. India Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
10.5.3.4. India Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
10.5.3.5. India Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
10.5.4. South Korea
10.5.4.1. South Korea Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.5.4.2. South Korea Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
10.5.4.3. South Korea Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
10.5.4.4. South Korea Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
10.5.4.5. South Korea Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
10.5.5. South-East Asia
10.5.5.1. South-East Asia Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.5.5.2. South-East Asia Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
10.5.5.3. South-East Asia Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
10.5.5.4. South-East Asia Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
10.5.5.5. South-East Asia Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
10.5.6. Rest of Asia Pacific
10.5.6.1. Rest of Asia Pacific Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
10.5.6.2. Rest of Asia Pacific Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
10.5.6.3. Rest of Asia Pacific Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
10.5.6.4. Rest of Asia Pacific Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
10.5.6.5. Rest of Asia Pacific Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)

11. Latin America Bacterial Pneumonia Market Analysis
11.1. Latin America Bacterial Pneumonia Market, by Disease Type, 2016-2028(US$ Bn)
11.1.1. Overview
11.1.2. SRC Analysis
11.2. Latin America Bacterial Pneumonia Market, by Drug Type, 2016-2028(US$ Bn)
11.2.1. Overview
11.2.2. SRC Analysis
11.3. Latin America Bacterial Pneumonia Market, by Dosage Form, 2016-2028(US$ Bn)
11.3.1. Overview
11.3.2. SRC Analysis
11.4. Latin America Bacterial Pneumonia Market, by Distribution Channel, 2016-2028(US$ Bn)
11.4.1. Overview
11.4.2. SRC Analysis
11.5. Latin America Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
11.5.1. Brazil
11.5.1.1. Brazil Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.5.1.2. Brazil Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
11.5.1.3. Brazil Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
11.5.1.4. Brazil Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
11.5.1.5. Brazil Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
11.5.2. Mexico
11.5.2.1. Mexico Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.5.2.2. Mexico Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
11.5.2.3. Mexico Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
11.5.2.4. Mexico Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
11.5.2.5. Mexico Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
11.5.3. Rest of Latin America
11.5.3.1. Rest of Latin America Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
11.5.3.2. Rest of Latin America Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
11.5.3.3. Rest of Latin America Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
11.5.3.4. Rest of Latin America Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
11.5.3.5. Rest of Latin America Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)

12. Middle East and Africa Bacterial Pneumonia Market Analysis
12.1. Middle East and Africa Bacterial Pneumonia Market, by Disease Type, 2016-2028(US$ Bn)
12.1.1. Overview
12.1.2. SRC Analysis
12.2. Middle East and Africa Bacterial Pneumonia Market, by Drug Type, 2016-2028(US$ Bn)
12.2.1. Overview
12.2.2. SRC Analysis
12.3. Middle East and Africa Bacterial Pneumonia Market, by Dosage Form, 2016-2028(US$ Bn)
12.3.1. Overview
12.3.2. SRC Analysis
12.4. Middle East and Africa Bacterial Pneumonia Market, by Distribution Channel, 2016-2028(US$ Bn)
12.4.1. Overview
12.4.2. SRC Analysis
12.5. Middle East and Africa Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
12.5.1. GCC Countries
12.5.1.1. GCC Countries il Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.5.1.2. GCC Countries Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
12.5.1.3. GCC Countries Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
12.5.1.4. GCC Countries Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
12.5.1.5. GCC Countries Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
12.5.2. South Africa
12.5.2.1. South Africa Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.5.2.2. South Africa Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
12.5.2.3. South Africa Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
12.5.2.4. South Africa Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
12.5.2.5. South Africa Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)
12.5.3. Rest of Middle East and Africa
12.5.3.1. Rest of Middle East and Africa Bacterial Pneumonia Market Estimates and Forecast, 2016-2028 (US$ Bn)
12.5.3.2. Rest of Middle East and Africa Bacterial Pneumonia, By Disease Type, 2016-2028 (US$ Bn)
12.5.3.3. Rest of Middle East and Africa Bacterial Pneumonia, By Drug Type, 2016-2028 (US$ Bn)
12.5.3.4. Rest of Middle East and Africa Bacterial Pneumonia, By Dosage Form, 2016-2028 (US$ Bn)
12.5.3.5. Rest of Middle East and Africa Bacterial Pneumonia, By Distribution Channel, 2016-2028 (US$ Bn)

13. Company Profiles
13.1. Pfizer, Inc
13.1.1. Company Overview
13.1.2. Products/Services Portfolio
13.1.3. Geographical Presence
13.1.4. Financial Summary
13.1.4.1. Market Revenue and Net Profit (2019-2021)
13.1.4.2. Business Segment Revenue Analysis
13.1.4.3. Geographical Revenue Analysis
13.2. Eli Lilly and Company
13.3. Lupin Pharmaceuticals, Inc
13.4. Sun Pharmaceutical Industries Ltd
13.5. Teva Pharmaceutical Industries, Ltd
13.6. Mylan N.V.
13.7. Sanofi
13.8. AstraZeneca plc
13.9. GlaxoSmithKline plc
13.10. Nabriva Therapeutics plc
13.11. Others

 

List of Figures

FIG. 1 Global Bacterial Pneumonia Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global Bacterial Pneumonia Market Segmentation
FIG. 4 Global Bacterial Pneumonia Market, by Disease Type, 2021 (US$ Bn)
FIG. 5 Global Bacterial Pneumonia Market, by Drug Type, 2021 (US$ Bn)
FIG. 6 Global Bacterial Pneumonia Market, by Dosage Form Type, 2021 (US$ Bn)
FIG. 7 Global Bacterial Pneumonia Market, by Distribution Channel, 2021 (US$ Bn)
FIG. 8 Global Bacterial Pneumonia Market, by Geography, 2021 (US$ Bn)
FIG. 9 Attractive Investment Proposition, by Disease Type, 2021
FIG. 10 Attractive Investment Proposition, by Drug Type, 2021
FIG. 11 Attractive Investment Proposition, by Dosage Form Type, 2021
FIG. 12 Attractive Investment Proposition, by Distribution Channel, 2021
FIG. 13 Attractive Investment Proposition, by Geography, 2021
FIG. 14 Global Market Share Analysis of Key Bacterial Pneumonia Market Manufacturers, 2021
FIG. 15 Global Market Positioning of Key Bacterial Pneumonia Market Manufacturers, 2021
FIG. 16 Global Bacterial Pneumonia Market Value Contribution, By Disease Type, 2021 & 2028 (Value %)
FIG. 17 Global Bacterial Pneumonia Market, by Community-acquired Pneumonia, Value, 2016-2028 (US$ Bn)
FIG. 18 Global Bacterial Pneumonia Market, by Healthcare-associated Pneumonia, Value, 2016-2028 (US$ Bn)
FIG. 19 Global Bacterial Pneumonia Market Value Contribution, By Drug Type, 2021 & 2028 (Value %)
FIG. 20 Global Bacterial Pneumonia Market, by Antibiotics, Value, 2016-2028 (US$ Bn)
FIG. 21 Global Bacterial Pneumonia Market, by Cough Medicine, Value, 2016-2028 (US$ Bn)
FIG. 22 Global Bacterial Pneumonia Market, by Pain Killer/Fever Reducers, Value, 2016-2028 (US$ Bn)
FIG. 23 Global Bacterial Pneumonia Market, by Vaccines, Value, 2016-2028 (US$ Bn)
FIG. 24 Global Bacterial Pneumonia Market Value Contribution, By Dosage Form, 2021 & 2028 (Value %)
FIG. 25 Global Bacterial Pneumonia Market, by Oral, Value, 2016-2028 (US$ Bn)
FIG. 26 Global Bacterial Pneumonia Market, by Intravenous, Value, 2016-2028 (US$ Bn)
FIG. 27 Global Bacterial Pneumonia Market Value Contribution, By Distribution Channel, 2021 & 2028 (Value %)
FIG. 28 Global Bacterial Pneumonia Market, by Hospital Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 29 Global Bacterial Pneumonia Market, by Retail Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 30 Global Bacterial Pneumonia Market, by Online Pharmacies, Value, 2016-2028 (US$ Bn)
FIG. 31 U.S. Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 32 Canada Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 33 Germany Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 34 France Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 35 U.K. Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 36 Italy Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 37 Spain Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 38 Rest of Europe Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 39 China Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 40 Japan Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 41 India Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 42 South Korea Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 43 Southeast Asia Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 44 Rest of Asia Pacific Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 45 Latin America Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 46 Brazil Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 47 Mexico Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 48 Rest of Latin America Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 49 Middle East & Africa Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 50 GCC Countries Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 51 South Africa Bacterial Pneumonia Market, 2016-2028 (US$ Bn)
FIG. 52 Rest of Middle East and Africa Bacterial Pneumonia Market, 2016-2028 (US$ Bn)

List of Tables

TABLE 1 Market Snapshot: Global Bacterial Pneumonia Market
TABLE 2 Global Bacterial Pneumonia Market, by Competitive Benchmarking, 2021
TABLE 3 Global Bacterial Pneumonia Market, by Geographical Presence Analysis, 2021
TABLE 4 Global Bacterial Pneumonia Market, by Key Strategies Analysis, 2021
TABLE 5 Global Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 6 Global Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 7 Global Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 8 Global Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 9 Global Bacterial Pneumonia Market, by Geography, 2016-2028 (US$ Bn)
TABLE 10 North America Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 11 North America Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 12 North America Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 13 North America Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 14 North America Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
TABLE 15 US Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 16 US Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 17 US Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 18 US Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 19 Canada Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 20 Canada Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 21 Canada Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 22 Canada Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 23 Europe Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 24 Europe Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 25 Europe Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 26 Europe Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 27 Europe Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
TABLE 28 Germany Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 29 Germany Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 30 Germany Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 31 Germany Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 32 France Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 33 France Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 34 France Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 35 France Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 36 UK Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 37 UK Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 38 UK Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 39 UK Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 40 Italy Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 41 Italy Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 42 Italy Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 43 Italy Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 44 Spain Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 45 Spain Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 46 Spain Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 47 Spain Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 48 Rest of Europe Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 49 Rest of Europe Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 50 Rest of Europe Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 51 Rest of Europe Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 52 Asia Pacific Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 53 Asia Pacific Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 54 Asia Pacific Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 55 Asia Pacific Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 56 Asia Pacific Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
TABLE 57 China Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 58 China Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 59 China Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 60 China Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 61 Japan Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 62 Japan Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 63 Japan Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 64 Japan Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 65 India Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 66 India Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 67 India Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 68 India Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 69 South Korea Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 70 South Korea Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 71 South Korea Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 72 South Korea Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 73 South East Asia Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 74 South East Asia Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 75 South East Asia Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 76 South East Asia Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 77 Rest of Asia Pacific Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 78 Rest of Asia Pacific Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 79 Rest of Asia Pacific Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 80 Rest of Asia Pacific Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 81 Latin America Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 82 Latin America Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 83 Latin America Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 84 Latin America Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 85 Latin America Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
TABLE 86 Brazil Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 87 Brazil Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 88 Brazil Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 89 Brazil Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 90 Mexico Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 91 Mexico Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 92 Mexico Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 93 Mexico Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 94 Rest of Latin America Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 95 Rest of Latin America Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 96 Rest of Latin America Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 97 Rest of Latin America Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 98 Middle East and Africa Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 99 Middle East and Africa Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 100 Middle East and Africa Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 101 Middle East and Africa Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 102 Middle East and Africa Bacterial Pneumonia Market, by Country, 2016-2028 (US$ Bn)
TABLE 103 GCC Countries Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 104 GCC Countries Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 105 GCC Countries Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 106 GCC Countries Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 107 South Africa Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 108 South Africa Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 109 South Africa Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 110 South Africa Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)
TABLE 111 Rest of Middle East and Africa Bacterial Pneumonia Market, by Disease Type, 2016-2028 (US$ Bn)
TABLE 112 Rest of Middle East and Africa Bacterial Pneumonia Market, by Drug Type, 2016-2028 (US$ Bn)
TABLE 113 Rest of Middle East and Africa Bacterial Pneumonia Market, by Dosage Form, 2016-2028 (US$ Bn)
TABLE 114 Rest of Middle East and Africa Bacterial Pneumonia Market, by Distribution Channel, 2016-2028 (US$ Bn)

Frequently Asked Questions:

How does COVID-19 Impact Bacterial Pneumonia?

The coronavirus pandemic has also impeded the development, manufacture, and distribution of medications and other healthcare products, as well as the growth of the healthcare sectors of many businesses globally.

Which is the leading region for Bacterial Pneumonia?

North America held the largest market share for Bacterial Pneumonia.

What are the key dynamics for the growth of Bacterial Pneumonia?

Antibiotics are becoming less effective at treating bacterial pneumonia due to the rise in bacterial resistance. Pharmaceutical industry innovation is constantly focused on developing new kinds of antibiotics. These are the driving factor for this market.

Which is the major segment in Bacterial Pneumonia by Disease Type?

Community-acquired Pneumonia segment had a major share in 2021.

Which is the major segment of Bacterial Pneumonia by Drug Type?

Antibodies segment had a major share in the global market in 2021.

Antiviral Drugs Market

Published:
Report ID: 40681

AI in Oncology Market

Published:
Report ID: 40668

Automated Liquid Handling Systems Market

Published:
Report ID: 40663

Non Infectious Macular Edema Treatment Market

Published:
Report ID: 7337

U.S. Medical Device Contract Manufacturing Market

Published:
Report ID: 40557

Endoscopes Market

Published:
Report ID: 40551

Animal Wound Care Market

Published:
Report ID: 40564

Adeno Associated Viral Vector Market

Published:
Report ID: 40601

AI Based Drug Discovery Market

Published:
Report ID: 40608

Intravitreal Injectable Market

Published:
Report ID: 7250

Pharmacogenomics Market

Published:
Report ID: 9486

Nosocomial Infection Treatment Market

Published:
Report ID: 14189

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN